UA88869C2 - Соединения для нормализации цикла сон/бессонница - Google Patents

Соединения для нормализации цикла сон/бессонница

Info

Publication number
UA88869C2
UA88869C2 UAA200506506A UA2005006506A UA88869C2 UA 88869 C2 UA88869 C2 UA 88869C2 UA A200506506 A UAA200506506 A UA A200506506A UA 2005006506 A UA2005006506 A UA 2005006506A UA 88869 C2 UA88869 C2 UA 88869C2
Authority
UA
Ukraine
Prior art keywords
sleep
wake cycle
normalization
compounds
containing compound
Prior art date
Application number
UAA200506506A
Other languages
English (en)
Ukrainian (uk)
Inventor
Перри Ф. Реншоу
Скотт ЛУКАС
Original Assignee
Зе Маклин Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Маклин Хоспитал Корпорейшн filed Critical Зе Маклин Хоспитал Корпорейшн
Publication of UA88869C2 publication Critical patent/UA88869C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается способа нормализации цикла сон/бессонница у млекопитающего, который включает пероральное введение млекопитающему терапевтически эффективного количества соединения, которое выбирается из группы, которая состоит из соединения, которое содержит цитидин, соединение, которое содержит цитозин, и соединение, которое содержит уридин, нормализуя таким образом цикл сон/бессонница указанного млекопитающего, при этом указанное млекопитающее не страдает от бессонницы.
UAA200506506A 2002-12-20 2003-12-17 Соединения для нормализации цикла сон/бессонница UA88869C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
UA88869C2 true UA88869C2 (ru) 2009-12-10

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200506506A UA88869C2 (ru) 2002-12-20 2003-12-17 Соединения для нормализации цикла сон/бессонница

Country Status (12)

Country Link
US (1) US20040176316A1 (ru)
EP (1) EP1589979A4 (ru)
JP (2) JP4717444B2 (ru)
CN (1) CN100563660C (ru)
AU (1) AU2003299715A1 (ru)
BR (1) BR0317586A (ru)
CA (1) CA2508995A1 (ru)
MX (1) MXPA05006781A (ru)
NO (1) NO20052987L (ru)
RU (1) RU2366428C2 (ru)
UA (1) UA88869C2 (ru)
WO (1) WO2004058160A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
EP1565055B1 (en) * 2002-11-08 2013-06-12 THE McLEAN HOSPITAL CORPORATION Compounds for the treatment of tobacco dependence and withdrawal
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
PL1888081T3 (pl) * 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
AU2008322414C1 (en) * 2007-11-16 2014-05-01 International Ip Holdings Llc Edible energy composition with low caffeine
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
JP6165852B2 (ja) * 2012-06-04 2017-07-19 ファイザー・インク 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用
KR102245628B1 (ko) * 2013-04-05 2021-04-28 라이온 가부시키가이샤 내복 조성물
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
PT100525B (pt) * 1991-05-29 1999-10-29 Abbott Lab Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
AU4070597A (en) * 1996-08-16 1998-03-06 The Texas A & M University System Modifying insect cell gylcosylation pathways with baculovirus expression vectors
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
WO2000006174A1 (en) * 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
JP4717444B2 (ja) 2011-07-06
RU2005122934A (ru) 2006-01-20
MXPA05006781A (es) 2005-09-30
US20040176316A1 (en) 2004-09-09
EP1589979A2 (en) 2005-11-02
JP2011102319A (ja) 2011-05-26
BR0317586A (pt) 2005-11-22
CN100563660C (zh) 2009-12-02
EP1589979A4 (en) 2009-04-01
CN1750833A (zh) 2006-03-22
CA2508995A1 (en) 2004-07-15
RU2366428C2 (ru) 2009-09-10
AU2003299715A8 (en) 2004-07-22
JP2006513214A (ja) 2006-04-20
WO2004058160A3 (en) 2005-03-31
NO20052987L (no) 2005-08-29
NO20052987D0 (no) 2005-06-17
WO2004058160A2 (en) 2004-07-15
AU2003299715A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
UA88869C2 (ru) Соединения для нормализации цикла сон/бессонница
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
TW200518755A (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
MX2007002816A (es) Metodos para tratar un trastorno.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
GEP20104895B (en) Preparation of pregabalin and related compounds
WO2003080566A3 (en) Hif hydroxylase inhibitors
WO2006000547A3 (de) Verfahren zur herstellung eines phosphatadsorbens auf eisensulfat-basis
SI2044043T1 (sl) 1-2(-2,4-dimetilfenilsulfanil) -fenil)piperazin kot spojina s kombinirano serotoninsko ponovno postavitvijo, 5-ht3 in 5-ht1a aktivnost za zdravljenje kognitivnih poĺ kodb
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
RS91004A (en) Methods of treating ileus
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
IL190730A0 (en) Potassium channel inhibitors
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
TW200627740A (en) Earthquake-safe server-rack
WO2007053284A3 (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
EP1667685A4 (en) INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL
WO2003078574A3 (en) Novel metabolic targets and markers